Business Of Biotech (Matt Pillar)
Explorez tous les épisodes de Business Of Biotech
| Date | Titre | Durée | |
|---|---|---|---|
| 14 Feb 2022 | Plant-Based Biologics With iBio's Randy Maddux | 00:50:36 | |
We love to hear from our listeners. Send us a message. iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma's attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company's FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small. For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 21 Feb 2022 | Regulatory Harmonization With Aurion Biotech's Dr. Daniela Drago | 00:41:58 | |
We love to hear from our listeners. Send us a message. If you're taking a candidate into clinical trials that will be monitored by multiple international regulatory bodies, this episode is an absolute must-listen. Dr. Daniela Drago , Chief Regulatory Officer at Aurion Biotech, shares her encyclopedic knowledge of the dynamic regulatory harmonization landscape. Along the way, she offers concrete advice on creating multijurisdictional regulatory efficiencies that will smooth your journey through the clinic and beyond. Don't miss this one. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 28 Feb 2022 | AI-Driven Biologics With Fountain Therapeutics' William Greene, M.D | 00:49:40 | |
We love to hear from our listeners. Send us a message. With its hypothesis-free, target-free, AI-driven drug discovery platform, Fountain Therapeutics is turning the traditional drug discovery pathway on its ear to address a variety of age-related disease. On this week's episode of the Business of Biotech, Fountain CEO William Greene, M.D. joins us to discuss the approach, its rationale, and how the company is applying substantial support from the likes of Eli Lilly, Alexandria Venture Investments, R42 Group, Khosla Ventures, and Nan Fung Life Sciences. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 07 Mar 2022 | CAR T-cells For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D. | 00:55:33 | |
We love to hear from our listeners. Send us a message. While success has been seen in animal models, solid tumors have proved a vexing challenge for CAR T-cell therapies. On this week's episode of the Business of Biotech, we're joined by Anixa Biosciences Chairman, President, & CEO Amit Kumar, Ph.D. Dr. Kumar shares on the company's progress with a CAR T-cell therapy that aims to attack both tumor cells and the tumor vasculature, in hopes that it might be the first to destroy solid ovarian cancers. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 14 Mar 2022 | Lipid Nanoparticle Gene Coding With SalioGen Therapeutics' Ray Tabibiazar, M.D. | 00:50:03 | |
We love to hear from our listeners. Send us a message. This episode of the Business of Biotech is fire. In fact, it's an interview with SalioGen Therapeutics Chairman and CEO Ray Tabibiazar, M.D., whose last name literally translates to "Dr. Fire." Learn how he got that name, what's shaped his technology-agnostic philosophy on therapeutic development, the advantages of a genome engineering technology that leverages proprietary mammal-derived enzymes, rather than viruses, and how SalioGen is possibly carrying forth a pipeline that's 15 candidates deep and addressing eye, liver, heart, lung, bone marrow, and kidney diseases. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 21 Mar 2022 | Biotech M&A Trends With Allan Shaw | 00:50:03 | |
We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, Allan Shaw waxes on his expectations for mergers, acquisitions, and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. We tackle questions biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups that aren't prepared to take a candidate to the finish line have already conceded a major factor in partnership or buyout negotiations. Don't miss Shaw's advice for startup success in a suddenly tumultuous market. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 28 Mar 2022 | Gene Therapies For Ocular Disease With Sparing Vision's Stéphane Boissel | 00:56:20 | |
We love to hear from our listeners. Send us a message. Since assuming the President and CEO role at Sparingvision in August, 2020, Stéphane Boissel has been making big moves in the arenas of talent acquisition and IP expansion. Those efforts are securing the company's development of a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company's foundation story and the role venture philanthropy played in it, his strategy for attracting and retaining big-league talent, and the why behind his vigorous allegiance to internal development. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 04 Apr 2022 | Antibodies For Severe Allergies With IgGenix's Jessica Grossman, M.D. | 00:38:55 | |
We love to hear from our listeners. Send us a message. In this wide-ranging discussion, IgGenix CEO Jessica Grossman, M.D. discusses the application of and market opportunity for antibody therapy for severe allergies, the gender gap in the biopharma c-suite, why women work harder than men, what it means to be a female biopharma leader, and IgGenix's approach at isolating and re-engineering allergen-specific IgE antibodies into IgG antibodies designed to alleviate — and possibly prevent — allergic cascade. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 11 Apr 2022 | Commensal Viral Vectors with Ring Therapeutics' Tuyen Ong, M.D. | 00:46:52 | |
We love to hear from our listeners. Send us a message. When Tuyen Ong was a child, he and his family escaped Vietnam by boat in the dead of the night, bound for an Indonesian refugee camp. They spent a year in that camp before emigrating to the U.K., where Ong’s underprivileged adolescence found him growing up in the projects of London. Against the odds, Ong worked his way to UCL for an education that culminated with an M.D. Today, he’s CEO of Ring Therapeutics, a promising emerging biotech backed by Flagship Pioneering, the kingmaker behind the rise of Moderna. On this episode of the Business of Biotech, Ong shares on his challenging formative years, the unspoken love between a father and son, facing down racism as a poor Chinese kid in Vietnam and London, and how those experiences shape his leadership at Ring. Oh, and we talk about some really great science, too. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 18 Apr 2022 | Gynecological Cancer Therapies with Context Therapeutics' Martin Lehr | 00:47:07 | |
We love to hear from our listeners. Send us a message. Context Therapeutics Co-Founder & CEO Martin Lehr shares stories from his self-described "recovery from venture capital," the work his company is doing in gynecological cancers, and how his small company manages a modality-agnostic approach and investigator-sponsored trials across multiple clinical candidates, four of which are in phase 2 clinical trials. We also discuss his "extracurricular" work with BioBreak, Life Science Leader, and Life Science Cares, and why those organizations are important to him personally and professionally. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 25 Apr 2022 | Fighting Blindness & Funding The Fight With Opus Genetics' CEO Ben Yerxa, Ph.D. | 00:46:25 | |
We love to hear from our listeners. Send us a message. Opus Genetics is an early-stage gene therapy company launched just last year and in unique fashion on the back of the patient advocacy group the Retinal Degeneration Fund. Already, its pipeline has developed into three candidates, the lead among them addressing Leber congenital amaurosis. Opus CEO Ben Yerxa, Ph.D. serves in triplicate as CEO at the RD Fund, Foundation Fighting Blindness, and Opus Genetics. His plate is full, but he's a man on a mission. On this episode of the Business of Biotech, Dr. Yerxa shares his story, that of Opus Genetics' unique approach to addressing inherited retinal diseases, and how the company is addressing current development and capacity challenges in the cell & gene manufacturing space. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 09 May 2022 | Live Biologics & The Microbiome With 4D pharma's Duncan Peyton | 00:51:08 | |
We love to hear from our listeners. Send us a message. 4D pharma's flagship early-stage clinical candidates are live biotherapeutics, a relatively new class of biologics that seek to impact disease state by modulating the microbiome. CEO Duncan Peyton is leading the effort to understand how the health of the microbiome relates to a wide range of diseases, including immuno-oncology, central nervous system disorders, respiratory disease, auto immune indications, and gastro intestinal disease. 4D pharma is even working on a live biotherapeutic vaccine platform. Join Duncan on this episode of the Business of Biotech as we discuss this new frontier of therapeutic exploration. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 02 May 2022 | Gene Tx For Renal Disease With Purespring CEO Richard Francis | 00:57:15 | |
We love to hear from our listeners. Send us a message. Purespring Therapeutics launched in 2020 on the back of IP developed by renowned kidney researcher Prof. Moin Saleem, who spent decades working on podocytes when podocytes weren’t cool. Just two years later, the company boasts three gene therapy assets and a platform developed expressly to identify new therapeutic targets to address kidney disease. These assets promise to change the "dialysis or transplant" ultimatums associated with kidney disease, where therapeutic innovation has been scarce. Under the leadership of CEO Richard Francis, the young company is operating with the audacious goal to take its therapeutics all the way to the commercial finish line. On this episode of the Business of Biotech, Francis offers a transparent look at the company’s growth strategy and the progress it’s achieved to date. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 16 May 2022 | Running Interference: RNAi with Silence Therapeutics' Craig Tooman | 00:30:44 | |
We love to hear from our listeners. Send us a message. Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of gene silencing candidates. Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease to rare diseases. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 23 May 2022 | What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D. | 01:06:51 | |
We love to hear from our listeners. Send us a message. As COVID-19 cases climb yet again, the Business of Biotech catches up with Tonix Pharmaceuticals CEO Seth Lederman, M.D. for a conversation on his company's multi-pronged strategy to advance vaccine and therapeutic candidates to address the disease and its variants. In addition to sharing on his journey from academia to industry, Dr. Lederman discusses his company's approach to grabbing its share of the highly competitive, and highly lucrative, vaccine market. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 30 May 2022 | Inflammation & Antibodies with Ampio Pharmaceuticals' Mike Martino, CEO | 00:56:17 | |
We love to hear from our listeners. Send us a message. Ampio Pharmaceuticals is currently weaving the gauntlet of a clinical hold triggered by COVID's disruption to clinical studies of its lead candidate Ampion, and recently launched an independent investigation into that trial and others. On this episode, Ampio Pharmaceuticals chairman and CEO Mike Martino joins the Business of Biotech for a candid discussion on the company, the candidate, the disruption, and the go-forward plan. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 06 Jun 2022 | The Biotech Beatdown With Allan Shaw | 00:46:25 | |
We love to hear from our listeners. Send us a message. On this, the 100th episode of the Business of Biotech podcast, our dear friend, frequent guest, and business of biotech brainiac Allan Shaw joins us to dissect the beleaguered biotech capital markets. We pick apart what's driving sentiment, whether the industry is over-inventoried, what's getting funded , what's not, and why, and what biotech leaders should be doing in an investment landscape marked by hyper-discernment. We also reflect on the podcast journey and celebrate the 100-episode milestone! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 13 Jun 2022 | Pyxis Oncology's Lara Sullivan, M.D. On Site-Specific ADCs And Change Management | 00:58:35 | |
We love to hear from our listeners. Send us a message. To fully appreciate the work Pyxis Oncology is doing in its development of site-specific ADCs for a number of oncological indications under the leadership of Lara Sullivan, M.D., you need to understand the work that shaped her leadership style. On this episode of the Business of Biotech, Dr. Sullivan shares the science and technology driving progress at Pyxis, but she also serves up a master class on change management, honed during her tenure managing high-stakes product portfolios at Pfizer. If you want to be a better leader, don't miss this one. And for more on Dr. Sullivan's journey, read this recent feature story at Life Science Leader magazine. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 20 Jun 2022 | Fibroblasts In Regenerative Medicine with FibroBiologics' Pete O'Heeron & Dr. Hamid Khoja | 00:55:47 | |
We love to hear from our listeners. Send us a message. FibroBiologics Chairman, CEO, & Founder Pete O'Heeron shares the journey that led him from clinical care to biopharma entrepreneurship, and he's joined by Chief Scientific Officer Hamid Khoja, Ph.D., who explains the manufacturing technology that's driving the company's exploitation of fibroblasts to develop regenerative therapies for indications ranging from degenerative disk disease and multiple sclerosis to cancer immunotherapies and therapeutics. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 27 Jun 2022 | Antibody-Cytokine Combinations With Philogen's Dr. Dario Neri | 00:44:09 | |
We love to hear from our listeners. Send us a message. Swiss-Italian biopharma company Philogen was co-founded in 1996 by three brothers, all of them PhDs. This unique family affair has fueled the development of an incredibly deep and advanced pipeline of no fewer than ten therapeutic products, most of them in oncology, contributing to 16 active clinical trials, three of them at Phase 3. On this episode of the Business of Biotech, co-founder, CEO, and CSO Prof. Dario Neri shares the incredible story of the company's progress and explains Philogen's approach to delivering bioactive agents to the site of disease using antibodies or small organic ligands, thus increasing therapeutic activity and helping spare normal tissues. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 04 Jul 2022 | Antibody Cocktails With Immunome's Dr. Purnanand Sarma | 00:47:15 | |
We love to hear from our listeners. Send us a message. Immunome CEO Purnanand Sarma, Ph.D. joins the Business of Biotech for a discussion on precision antibodies and his company's discovery platform, which identifies novel therapeutic antibodies and their antigen targets by leveraging highly educated memory B cells from patients who have learned to fight off their disease. It’s kind of like picking an all-star team of players who have been in the game, and who are well-trained to win. On today's episode we'll learn how they’re discovered, how they’re developed, and how they’re applied in cancer and coronavirus. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 11 Jul 2022 | Innate Immunity & Mouse Models With LIfT Biosciences' Alex Blyth | 00:58:02 | |
We love to hear from our listeners. Send us a message. Serial inventor and entrepreneur Alex Blyth had long held interests in health and science, but losing his mom to pancreatic cancer was the inflection point that launched LIfT Biosciences in 2016. Now, the preclinical company is on a mission to develop the world's first 'off-the-shelf' cell therapy to destroy all solid tumors, irrespective of strain or mutation, beginning with pancreatic cancer. On this episode of the Business of Biotech, Blyth shares the company's scientific approach and progress, and we explore the shortcomings of legacy clinical protocols including the inherent problems and limitations of mouse models. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 18 Jul 2022 | Changing The Diabetes Care Paradigm With Arecor's Dr. Sarah Howell | 00:59:02 | |
We love to hear from our listeners. Send us a message. While renal disease treatment technologies have seen moderate incremental improvements, there hasn't been a step-change advance in diabetes care since the discovery of insulin more than 100 years ago. Working with manufacturers of existing diabetes therapeutics in addition to advancing its own pipeline, Arecor is developing enhanced reformulations of tried-and-true therapeutics like insulin to improve a long-static standard of care. Arecor CEO Sarah Howell, Ph.D. joins the Business of Biotech for a discussion on the company's approach to improving the quality of life for some 200 million insulin-dependent patients worldwide. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 25 Jul 2022 | Oligonucleotide Opportunities in DMD with PepGen's James McArthur, Ph.D. | 00:36:29 | |
We love to hear from our listeners. Send us a message. Among the more prevalent genetic conditions, Duchenne muscular dystrophy affects an estimated one in 3,500 male births worldwide. It's caused by mutations of the DMD gene, which regulates the production of a protein called dystrophin. Approved DMD treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates derived from the company's Enhanced Delivery Oligonucleotide platform. The Business of Biotech caught up with Dr. McArthur at PepGen's Cambridge headquarters to learn more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 01 Aug 2022 | Creative Capital Generation With James Thomas Coates, Ph.D. | 00:51:00 | |
We love to hear from our listeners. Send us a message. As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table. To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space. The firm specializes in helping biotech startups realize direct routes to millions of dollars in federal funding from a host of not-so-intuitive federal institutions—NASA, and the US Navy, Air Force, and Army, for instance—and helping them optimize funding from more obvious federal agencies such as DARPA and the NIH. On this episode of the Business of Biotech, Dr. Coates shares strategies and resources for tapping into biopharma capital that's ripe for the taking. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 08 Aug 2022 | What's A Biologic Revolution? With Vaxxinity's Mei Mei Hu, J.D. | 00:52:43 | |
We love to hear from our listeners. Send us a message. Vaxxinity CEO Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On this week's Business of Biotech podcast, Mei Mei joins me to share Vaxxinity's strategy, what "democratization" and "revolution" really mean, why traditional vaccines and biologic therapies are converging to form the "third biologic revolution," and a whole lot more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 15 Aug 2022 | Observations On Outsourcing With Molecule to Market's Raman Sehgal | 01:00:55 | |
We love to hear from our listeners. Send us a message. Raman Sehgal has made a career out of putting his energy— and he's got a lot of it— into building biotech outsourcing companies and the people who make them run. After years spent supporting several from within, he launched ramarketing, a firm dedicated to helping CROs, CDMOs, CPOs, and other providers to the biotech ecosystem build their businesses, in 2009. He's also an international best-selling author (The Floundering Founder), co-founder of life sciences recruitment firm Lead Candidate, and founder & host of the Molecule to Market podcast. On this week's episode of the Business of Biotech, Raman brings us his unique and multifaceted perspectives on the biopharma outsourcing space, the bear biotech markets, and how both are impacting the work of early- and clinical-stage biopharma leaders. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 22 Aug 2022 | Biotech M&A Anomalies With Allan Shaw | 00:49:49 | |
We love to hear from our listeners. Send us a message. While many clinical-stage biopharmas are contracting or holding the line through the current market slump, Portage Biotech leaders Ian Walters, Allan Shaw, and company are making moves. The company recently acquired Tarus Therapeutics and iOx Therapeutics Ltd., extending its pipeline and positioning itself to meet some aggressive investor expectations. On this episode of the Business of Biotech, Shaw dissects the deals, digging into the M&A strategy at Portage and offering advice from the batter's box to leaders of early-stage biotechs. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 29 Aug 2022 | Genetic Testing & Neurodegenerative Disorders With AviadoBio's Lisa Deschamps | 00:52:41 | |
We love to hear from our listeners. Send us a message. Lisa Deschamps' story is one of determination and fortitude. She got her start in the life sciences where it begins and ends for many— "carrying the bag" in big pharma sales—then proceeded to crush the odds on her way to the C-suite at Novartis. Today, she's CEO at AviadoBio, a disruptive gene therapy startup prepping an intra-thalamic Frontotemporal Dementia candidate for the clinic with a heavy Series A in its hip pocket. On this episode of the Business of Biotech we get to know Lisa, her company and its therapeutic approach, her advocacy for genetic testing, and how she's applying her determination and fortitude to enabling more women to become life science leaders. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 05 Sep 2022 | Pursuit Of A Universal Flu Vaccine With Longhorn Vaccines & Diagnostics' Jeff Fischer | 00:57:09 | |
We love to hear from our listeners. Send us a message. With a unique multi-target approach, what it considers the world's best adjuvant, and a host of learnings from the successes and failures of COVID-19 vaccine efforts, Longhorn Therapeutics is gaining steam in its pursuit of a universal influenza vaccine. On this episode of the Business of Biotech, Longhorn Vaccines & Diagnostics Co-Founder and President Jeff Fischer gives us a transparent look at the science and the partnerships that are giving him cause to believe his company will succeed where so many have failed. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 12 Sep 2022 | IDO Target Perseverence With IO Biotech's Mai-Britt Zocca, Ph.D. | 00:37:53 | |
We love to hear from our listeners. Send us a message. Under the leadership of Mai-Britt Zocca, Ph.D., IO Biotech is advancing novel, immune-modulating cancer therapies targeting IDO (indoleamine 2,3-dioxygenase). Though promising, the target fell out of favor after some high-profile misses – most notably Merck's Phase 3 failure with pembrolizumab in 2018. But Immunome's dual mechanism of action is renewing interest in the target, and Dr. Zocca is gaining confidence as the company's data grows. On this episode of the Business of Biotech, she shares the approach, how it differs from previous attempts, and how her company is working to advance its programs in the wake of IDO's fall from grace. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 19 Sep 2022 | Epigenomic Programming With Omega Therapeutics' Mahesh Karande | 01:01:45 | |
We love to hear from our listeners. Send us a message. Using computational biology to hasten the effort, Omega Therapeutics' plan is to "coopt nature's universal biological operating system for gene control and cell differentiation." On this episode of the Business of Biotech, we dig into exactly what that means. We also explore the company's preclinical ambitions, which are diverse, targeting regenerative, multigenic/immunologic, oncologic, and monogenic indications. Omega is leaning heavily into computational biology along the way, having mapped what CEO Mahesh Karande characterizes as 95% of the IGD landscape. Learn how Karande intends to maintain momentum on this episode of the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 26 Sep 2022 | Regenerative Wound Care With BioStem Technologies' Jason Matuszewski & Andrew VanVurst | 01:01:16 | |
We love to hear from our listeners. Send us a message. Here's the story of BioStem, it's young founders, and how they reached commercial status in short order with a portfolio of proprietary regenerative wound care products developed from perinatal tissue. Fueled by a personal story of resilience and inspiration, Jason Matuszewski (CEO) and Andrew VanVurst (COO) built a company that's developed a local microenvironment activation platform drawing on a combination of small molecules, cytokines, and growth factors to promote tissue repair and regrowth. The company's internal development and cGMP manufacturing facilities have already yielded three approved products poised to change the paradigm for diabetic, traumatic, and other wound care. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 03 Oct 2022 | IND For TIL Therapy With Obsidian Therapeutics' Paul Wotton, Ph.D. | 00:47:28 | |
We love to hear from our listeners. Send us a message. On this episode of The Business of Biotech, Obsidian Therapeutics CEO Paul Wotton, Ph.D. takes us behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called OBX-115. Learn how the company navigated the regulatory path for a first-of-its-kind biologic therapy developed in partnership with the University of Texas MD Anderson Cancer Center that Dr. Wotton says, should it succeed, will eliminate the patient risk associated with concomitant IL2 therapy and improve clinical outcomes for certain patients with metastatic melanoma. We also get an update on outcomes from Obsidian's unique approach to solving COVID-19 challenges covered on episode 9 of the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 10 Oct 2022 | Oncology Discovery Advances With AbbVie's Steve Davidsen, Ph.D. | 00:40:14 | |
We love to hear from our listeners. Send us a message. AbbVie VP of Oncology Discovery Research Steve Davidsen, Ph.D. is a living, breathing timeline of the company's cancer research and development efforts. He got his start with the company— Abbott at the time— way back in 1986. As such, he's charted the adoption of multiple advanced technologies that have contributed to the realization of dozens of molecular weapons in the fight against cancer. On this episode of the Business of Biotech, Dr. Davidsen shares the latest on AbbVie's adoption of computational biology and how it's contributing to discovery and development efficiencies, why he's an AbbVie "lifer," how he manages and motivates a large team of research scientists, and a whole lot more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 17 Oct 2022 | Anatomy Of A VC Deal With 4BIO's Dima Kuzmin & Ray Therapeutics' Paul Bresge | 00:54:10 | |
We love to hear from our listeners. Send us a message. In a particularly candid conversation, 4BIO Managing Partner Dmitry ‘Dima’ Kuzmin and Ray Therapeutics Co-Founder & CEO Paul Bresge share the recipe for a successful relationship between biotech VC firm and startup. Bresge offers insight into VC engagement strategy and pitch, Kuzmin dishes on what investors look for in terms of "fundability" and what throws red flags, such as— perhaps ironically— a CEO like Bresge who has a deep and incredibly personal connection to the indication he's pursuing. The pair also discuss, in real and tangible terms, what constitutes a material, cultural match. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 24 Oct 2022 | Engineering Proteins For Food Allergies With Ukko's Dr. Anat Binur | 00:49:45 | |
We love to hear from our listeners. Send us a message. Anat Binur, Ph.D. is CEO and Co-Founder at Ukko, where she's leading an effort to create new allergy therapeutics by engineering the proteins that induce immune response in people who suffer from food allergies. The effort at Ukko is deeply rooted in computational biology. The company leverages artificial intelligence to analyze how the allergen proteins interact with patients' blood in an effort to determine the specific attributes of the proteins that trigger immune response. Then, it applies a unique combination of compute power and biology to identify and understand the changes it wants to engineer and predict the best possible designs. Learn how Ukko is fostering a culture of IT and biology collaboration and what lured this dynamic entrepreneur into biopharma on this episode of the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 31 Oct 2022 | Leveraging Lymph Nodes With Elicio's Dr. Peter DeMuth | 00:43:38 | |
We love to hear from our listeners. Send us a message. MIT-born startup Elicio Therapeutics' novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads. We caught up with Chief Scientific Officer Peter DeMuth, Ph.D. at Elicio HQ in Boston to learn how the platform works, and how it's driving rapid clinical progress for the company's robust pipeline of therapeutic vaccines in oncology, as a cell therapy amplifier in liquid and solid tumor indications, and in prophylactic vaccines for infectious diseases like COVID-19. Dr. DeMuth also shares his journey as a young scientific founder, how he's managed the transition from academic scientist to the C-suite, and how he leans into his scientific training to make a killer home brew. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 07 Nov 2022 | Product vs. Platform With Surface's Vito Palombella, Ph.D. and Robert Ross, M.D. | 01:03:11 | |
We love to hear from our listeners. Send us a message. Earlier this month, Surface Oncology shared that it will open a second stage of its monotherapy trial of SRF388, an antibody targeting IL-27, on the heels of a promising phase 2 data readout. Shortly before that release, the Business of Biotech caught up with Surface's CSO Vito Palombella, Ph.D. and CEO Rob Ross, M.D. in the company's Cambridge, MA HQ. We discussed the first-of-its-kind target, the company's "product versus platform" strategy and how it fits in the industry's current "platform" vibe, the finer points of building and maintaining a startup bio culture, the difference between that Bob Ross and the Rob Ross, M.D., and whole lot more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 14 Nov 2022 | Tick-Derived Therapeutic Molecules With Akari Therapeutics' Rachelle Jacques | 00:43:06 | |
We love to hear from our listeners. Send us a message. Ticks are a scourge. They're vectors of multiple serious an debilitating diseases, and evolution has made them perfectly adept at attaching to their hosts—and potentially spreading those diseases virtually undetected— that ability owing to anti-inflammatory and anesthetic proteins in their saliva. But the emerging biotech Akari Therapeutics thinks there's a broad range of medicinal value in those proteins. They've painstakingly developed a recombinant version of one such tick saliva-derived protein, called nomacopan, and put it to work in phase 3 trials to treat rare but deadly severe hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). On this week's episode of the Business of Biotech, Akari President & CEO Rachelle Jacques tells us about the redeeming qualities of tick saliva and how her company is putting it to work. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 21 Nov 2022 | RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati | 00:51:59 | |
We love to hear from our listeners. Send us a message. Nutcracker Therapeutics is a preclinical biopharma company developing multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and Genitourinary tumors. On this episode of the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph.D. offers a comprehensive view of the RNA-based therapeutics landscape and sheds light on what he perceives as an advantageous position at Nutcracker— the capacity to manufacture RNA in-house. If you're curious about the expanding science behind RNA-based therapeutics and their application in biotech, this conversation with a scientist-turned-chief business officer (Nosrati earned his Ph.D. in Biochemistry and Molecular Biology) is a can't-miss episode. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 28 Nov 2022 | In-Vivo CAR T Update With Umoja Biopharma's David Fontana, Ph.D. | 00:53:07 | |
We love to hear from our listeners. Send us a message. 2023 is just around the corner, and it's shaping up to be a big year for Umoja Biopharma. The company is on the leading edge of the effort to break the solid tumor barrier with in vivo CAR T-cell therapies, with one such effort currently enrolling patients for a phase 1 trial. It's planning two more INDs in the coming year. This episode of the Business of Biotech finds us getting the inside story from Umoja Chief Operating Officer David Fontana, whose storied career includes leadership positions at heavyweights including Sanofi, SeaGen, Pfizer, Juno, and BMS. Fontana shares on how he applies his experience playing a lead role in the success of Breyanzi, Adcetris, Bavencio, and Relatlimab in his new role at Umoja, the outsourcing battle scars that motivated the company to build its own 146,000 square foot development and manufacturing facility, and much more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 05 Dec 2022 | The Antibody Engine With Abpro's Chan Brothers | 00:53:16 | |
We love to hear from our listeners. Send us a message. In an industry that takes new business naming conventions to extremes, Abpro is a refreshingly clear exception. Brothers Ian Chan (CEO & Co-Founder) and Eugene Chan, M.D., (Chairman & Co-Founder) are antibody pros. The company's pipeline spans no fewer than 8 antibody candidates aimed at COVID-19, cancers including breast, gastric, and liver, and ophthalmologic indications DME and wet AMD. With a scientific advisory board led by Bob Langer, Ph.D. of Moderna fame and a new partnership with global powerhouse Celltrion worth a potential $1.75 billion, the company's on the move. On this episode of the Business of Biotech, the Chan brothers take us behind the scenes of Abpro's progress. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 12 Dec 2022 | Gene Therapy For Chronic Inflammation With Xalud's Howard Rutman, M.D. | 00:47:00 | |
We love to hear from our listeners. Send us a message. While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger. Osteoarthritis, or OA, is a chronic, progressive joint disease that affects over 30 million people in the United States. On this episode of the Business of Biotech, we catch up with Xalud Chief Medical Officer Howard Rutman, M.D., MBA for a discussion on the company's late-stage plasmid DNA gene therapy that's showing promise in OA and other chronic inflammatory conditions. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 19 Dec 2022 | Allan Shaw On Financing Biopharma Innovation | 00:53:44 | |
We love to hear from our listeners. Send us a message. Friend and frequent guest Allan Shaw rejoins the Business of Biotech to reflect on his recent presentation on innovative biotech financing at the BioFuture event in NYC. We also dig into Bruce Booth's "Atlas Venture Year In Review," revisiting and unpacking some quoteworthy material and metrics from both sources. Allan offers up plenty of prognostication and professional insight in a preview of what's to come in 2023, complete with his signature "Allanisms" and colorful analogies. A can't-miss episode as we round the turn to a new year! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 26 Dec 2022 | AI & Computational Biology With Recursion's Chris Gibson, Ph.D. | 00:53:44 | |
We love to hear from our listeners. Send us a message. Recursion's unique, technology-aided approach to drug discovery has yielded one of the deepest, fastest-growing pipelines in emerging biotech. It starts with a 20-petabyte-and-growing database designed to create comprehensive "maps of biology" that enable insight into the relationships between molecules and cell types. On this episode of the Business of Biotech, we take a deep dive into the approach—and what Recursion intends to do with all that data—with the company's co-founder and CEO, Chris Gibson, Ph.D. Don't miss this window into the world of a true pioneer in computational biology. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 02 Jan 2023 | Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany | 00:31:52 | |
We love to hear from our listeners. Send us a message. Join Matt Pillar for a conversation with Carine Boustany, PharmD and SVP, US Research Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim. On this episode of the Business of Biotech, we walk through the story leading up to the recent approval of spesolimab. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults. Dr. Boustany shares the antibody's fortuitous discovery, the challenges her team faced on the path to approval, and how those challenges were overcome. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 09 Jan 2023 | Computational Drug Discovery With Gain Therapeutics' Matthias Alder | 00:57:16 | |
We love to hear from our listeners. Send us a message. Gain Therapeutics' newly-appointed CEO Matthias Alder offers up a deep, yet abundantly clear explanation of how his company is applying compute power to speed up drug discovery. At Gain, computational models help researchers winnow down not just which molecules might have therapeutic effect, but also how adept those molecules will be at binding--and staying bound--to their target. It's not just theory, either. On this episode of the Business of Biotech, Alder shares on how the virtual successes seen on Gain's servers have translated in the wet lab, and how they've contributed to the company's fast-growing preclinical pipeline. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 16 Jan 2023 | Women In Biotech With Bill & Melinda Gates MRI's Piper Trelstad, Ph.D. | 00:31:00 | |
We love to hear from our listeners. Send us a message. After more than 21 years leading process, product, and technical development efforts at Merck and Takeda, Piper Trelstad, Ph.D. joined the Bill & Melinda Gates Medical Research Institute (MRI) in January, 2022. On this episode of the Business of Biotech, we'll dive into how the MRI, a full-fledged clinical-stage biopharmaceutical company, is tackling health problems that challenge some of the world's most vulnerable populations. Dr. Trelstad also shares her minority perspective as a woman working in a highly technical capacity in biopharma, and how the industry can proactively support and advance women in technical roles. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 23 Jan 2023 | Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed | 00:56:33 | |
We love to hear from our listeners. Send us a message. Call it fortuitous, good planning, instinct, or a combination of all three, but Nadim Ahmed's educational foundation— earned before the IT/Biology combination was cool— is serving him well as CEO at Cullinan Oncology. On this episode of the Business of Biotech, Ahmed shares his story and that of Cullinan Oncology's drug discovery efforts, which have yielded a wide range of multi-modal candidates spanning a range of cancer indications. Our discussion digs into the company's transition from R&D to the clinic, how its built an uncommonly comfortable cash position through partnership, and its ambition to become a fully-integrated commercial-stage biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 30 Jan 2023 | Building A Better COVID Vaccine With Ocugen's Shankar Musunuri, Ph.D. | 01:00:24 | |
We love to hear from our listeners. Send us a message. Is it past time for a new approach to the COVID vaccine? Ocugen Chairman of the Board, Founder & CEO Shankar Musunuri, Ph.D. says yes, and his ideals would mark significant improvements: fewer shots, better durability, less post-vaccination transmission, and safety proven by time-tested technology. How would such a vaccine be produced? Dr. Musunuri lays out the manufacturing science— and why the improved COVID vaccine his company is currently putting through Phase 2/3 trials makes good business sense—on this week's episode of the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 06 Feb 2023 | BoB@JPM: Support Of A Blossoming Pipeline With Sangamo's Sandy Macrae, Ph.D. | 00:48:36 | |
We love to hear from our listeners. Send us a message. SPECIAL EDITION: BoB@JPM Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 13 Feb 2023 | BoB@JPM: Academia To Industry With Oncolytics' Matt Coffey, Ph.D. | 00:36:42 | |
We love to hear from our listeners. Send us a message. SPECIAL EDITION: BoB@JPM Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 20 Feb 2023 | BoB@JPM: Post-IPO With Bolt Biotherapeutics' Drs. Randall Schatzman and Edith Perez | 00:33:39 | |
We love to hear from our listeners. Send us a message. SPECIAL EDITION: BOB@JPM Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 27 Feb 2023 | BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D. | 00:38:55 | |
We love to hear from our listeners. Send us a message. SPECIAL EDITION: BOB@JPM Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 06 Mar 2023 | BoB@JPM: Self-Replicating RNA With Elixirgen's Akihiro Ko | 00:43:28 | |
We love to hear from our listeners. Send us a message. SPECIAL EDITION: BoB@JPM Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 13 Mar 2023 | TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono | 01:10:01 | |
We love to hear from our listeners. Send us a message. Among a growing cluster of Pittsburgh biotechs, you'll find BlueSphere Bio, an early-stage company discovering T-cell receptors to leverage against tumor-specific antigens in individual cancer patients. Its leader, CEO Keir Loiacono, Esq., works with a sense of urgency inspired by his own cancer journey. Business of Biotech host Matt Pillar and guest co-host Jon O'Connell, executive editor at Bioprocess Online, toured Bluesphere's state-of-the-art facility perched on the bank of the Monongahela River. Then, we sat down with Loiacono to learn his story and discuss the company's vision for the future of personalized, adoptive cell therapy. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 20 Mar 2023 | Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D. | 00:56:10 | |
We love to hear from our listeners. Send us a message. On the surface, the merger of Medsenic (a developer of arsenic salt formulations for therapeutic application in inflammatory conditions) and Bone Therapeutics (which develops allogeneic cell therapies for complicated bone fractures) doesn't look obviously synergistic. But Francois Rieger, Ph.D. says that on the scientific level, it's a perfect union, and the veteran biotech founder says the business should always follow the science. The union of the two companies formed BioSenic, which Dr. Regier now serves as CEO. On this week's episode of the Business of Biotech, Dr. Regier shows us the good, the bad, and the ugly of the merger process and shares his philosophy on letting science lead the way, regardless of the analysts' takes. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 27 Mar 2023 | Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D. | 00:59:01 | |
We love to hear from our listeners. Send us a message. The more we learn about inflammation and the complex cause/contributor/symptom roles it plays in various disease states, the more business activity we see in the inflammation therapeutics space. But to date, commercial pharmaceutical and biologic efforts have fallen short for patients, says Moonlake Immunotherapeutics CEO Jorge Santos Da Silva, Ph.D. What's the problem, and why does he think his camelid-derived nanobody candidates are poised to outperform big-pharma standards from the likes of UCB and Novartis? Find out on this week's episode of the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 03 Apr 2023 | Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D. | 00:56:18 | |
We love to hear from our listeners. Send us a message. Today's episode of the Business of Biotech covers a lot of ground with Enzyvant CEO Bill Symonds, Pharm.D. Among other things, we discuss the career moves Dr. Symonds has made within the "vant" environment since his involvement in the launch of the original Roivant, the approval of Rethymic, the merger of Altavant and Enzyvant, and the company's intentions for a brand new regenerative medicine manufacturing facility in Research Triangle Park. From drug approvals to mergers, from internal manufacturing capacity to founders-turned-presidential candidates, this one's got it all. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 10 Apr 2023 | Functional Ectopic Organs with LyGenesis' Michael Hufford, Ph.D. | 00:51:24 | |
We love to hear from our listeners. Send us a message. LyGenesis is developing a pipeline of allogeneic cell therapies using the lymph node as an in vivo bioreactor to grow functioning ectopic organs. What sounds like science fiction to some is starting to look like a life changing therapy for millions of liver, kidney, pancreas, and thymus disease sufferers. The science behind it is being developed not in Boston, not in Philadelphia, nor in San Franciso, but right in the heart of the rust belt in Pittsburgh, PA. This week's episode of the Business of Biotech takes us there for a conversation with LyGenesis CEO Dr. Michael Hufford, Ph.D. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 17 Apr 2023 | Gene Tx For Hearing Loss with Sensorion's Nawal Ouzren | 00:54:18 | |
We love to hear from our listeners. Send us a message. We often talk about biotechs taking "big swings." This week's guest is swinging for the fences with a lineup of gene therapies designed to address multiple forms of hearing loss, which affect multiple millions (if not, billions) of people worldwide. Adding to the challenge she's accepted, Sensorion CEO Nawal Ouzren is architecting an approach that seeks to restore hearing that's been lost due to genetic factors, treat sudden hearing disorders, and proactively prevent hearing loss due to common causes such as cisplatin induced ototoxicity or cochlear implantation. Listen in as Ouzren shares her holistic and aggressive plans with the Business of Biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 24 Apr 2023 | Therapeutic Molecules From Moss with eleva's Andreas Schaaf and Björn Cochlovius, Ph.D. | 01:00:42 | |
We love to hear from our listeners. Send us a message. We kick this conversation off with the writer Elizabeth Gilbert's take on moss, which she so eloquenlty dubs a "resurrection engine." Gilbert almost certianly didn't realize the potential of moss to play a resurrectional role in human health, but Eleva Biotech's Andreas Schaaf and Bjorn Cochlovius do. On this episode of the Business of Biotech, we learn about a company that's developing proteins to fuel its own pipeline — and its partners' — from a most ubiquitous plant that grows virtually everywhere. It grows particularly well in bioreactors outfitted with custom grow lights, and presents some significant advantages over CHO cell line development. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 01 May 2023 | Building Flagship Pioneering With Avak Kahvejian, Ph.D. | 00:59:45 | |
We love to hear from our listeners. Send us a message. Flagship Pioneering is fertile ground for a bevy of blossoming biotechs, and one of its most prolific sowers is General Partner Avak Kahvejian, Ph.D. Dr. Kahvejian counts Seres Therapeutics, Rubius Therapeutics, Codiak BioSciences, Cygnal Therapeutics, Ring Therapeutics, Cellarity, Laronde, and Generate Biomedicines among the companies he's played a leading hand in launching. On this episode of the Business of Biotech, Kahvejian takes us under the hood of one of the most burgeoning businesses in biotech, sharing details on the people, processes, and technologies fueling its rapid growth. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 08 May 2023 | A More NIIMBL Biotech Workforce With John Balchunas | 01:03:07 | |
We love to hear from our listeners. Send us a message. What are biopharma's greatest skilled manufacturing labor needs, and what's the industry doing to fill them? John Balchunas is on the front lines in his position as Workforce Director at NIIMBL, the National Institute for Innovation in Manufacturing Biopharmaceuticals, and he says advanced degrees and pedigrees aren't the answer. The breadth and depth of NIIMBL's efforts to influence the next generation of the biopharma workforce — from high school vocational programs to community colleges and on-the-job development—might surprise you. Listen in as Balchunas brings the Business of Biotech up to speed on a training and development agenda that plants seeds early and often. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 15 May 2023 | Funding A Neurodegeneration Startup With Coya Therapeutics' Howard Berman | 00:49:30 | |
We love to hear from our listeners. Send us a message. Like many of us, Howard Berman, Ph.D. has personal experience with the tragedy of cognitive decline. Neurodegenerative disorders are on the rise, and when one afflicted his father — a triple board-certified physician — he saw firsthand that they don't discriminate. Berman has dedicated his career to addressing neuro, autoimmune, and metabolic diseases, having founded Nicoya Health in 2020 and overseeing its merger with Coya Therapeutics the following year. The company came out of the gates this year fueled by an 11th-hour 2022 IPO, one of just a dozen on the year. Berman joined the Business of Biotech to share his strategy during a stingy stretch in biotech capital markets. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 22 May 2023 | Resilient Biopharma Leadership With Ambrx's Dan O'Connor | 00:42:19 | |
We love to hear from our listeners. Send us a message. Since Dan O'Connor stepped in as CEO at Ambrx late last year, the company's stock has rallied on the revival of a previously-shelved anti-HER2 ADC. It also raised $78 million and completed its ATM (at-the-market) offering. O'Connor is no stranger to overcoming adversity. A former marine captain, he was among the first deployed to the Persian Gulf to fight in Operation Desert Shield. While his leadership at Ambrx is anything but militaristic, he ascribes much of his style, and certainly his approach to adverse conditions, to his military time. On this episode of the Business of Biotech, we welcome back Dan O'Connor to discuss the resuregence of Ambrx and leadership resilience in an industry that demands it. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 29 May 2023 | Propagating Peptides With Peptilogics' Jonathan Steckbeck, Ph.D. | 00:51:02 | |
We love to hear from our listeners. Send us a message. The Business of Biotech took a road trip to Pittsburgh to visit with Peptilogics CEO and founder Dr. Jonathan Steckbeck, whose Ph.D. work was inspired by the loss of his father-in-law to a hospital-borne infection. That work subsequently led to the formation of a company committed to leveraging peptide therapeutics to address PJI (prosthetic joint infection), cystic fibrosis infection, as well as rare genetic disease and oncological indications. Dr. Steckbeck walks us through the transition of his academic work into a clinical-stage company, how he's sustaining the company in a lean capital market, and the virtues of doing biotech business in Pittsburgh. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 05 Jun 2023 | The Innovation Reduction Act with Allan Shaw | 00:37:47 | |
We love to hear from our listeners. Send us a message. Allan Shaw isn't the only insider who's preemptively critical of the impact the IRA (Inflation Reduction Act) will have on the biopharma industry. Allan's back this week with analysis of what he and others are tongue-in-cheek calling the "innovation reduction act." He posits that the act's removal of certain protections will stifle momentum by disincentivizing the pursuit of novel discoveries in molecules small and large. He also suggests that the impact of the IRA will ultimately cost patients and payers more. Tune in to learn why. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 12 Jun 2023 | The Face Of African Biotech with Adrienne Leussa, Ph.D. | 01:04:21 | |
We love to hear from our listeners. Send us a message. Dr. Adrienne Leussa is one of my favorite follows. If the booming biotech scene on an incredibly diverse continent of 1.2 billion people interests you, she should be one of your faves, too. Dr. Leussa's intellect, energy, and glowing spirit contribute to her ambassadorship of the African biotech scene. She's an entrepreneur, a visionary, a communicator, and a tireless advocate for African biotech opportunity. On today's epsiode of the Business of Biotech, we share a lot of laughs as we learn how Adrienne's entrepreneurial beginnings selling nuts and lollies on the streets of Yaounde, Cameroon set the foundation for an accelerated academic career and a passion for bio business development. We also dive into Africa's growing biotech scene, discussing the support infrastructure available for budding entrepreneurs and the importance of technology transfer and commercial research innovations from local universities. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 19 Jun 2023 | Population-Level Health Impact With Vaxxinity's John Krayacich | 00:48:55 | |
We love to hear from our listeners. Send us a message. Vaxxinity’s John Krayacich likes taking big swings at big indications. He’s played key roles on the teams that launched Lipitor, Lyrica, and Neurontin, which have had measurable impacts on global populations of people suffering from cardiovascular disease, CNS disorders, and pain. He found those opportunities at companies like LEO, Novartis, Parke Davis, and Pfizer. Now, Krayacich is taking big swings at a new set of incredibly challenging candidates—immunotherapeutic vaccines for neurodegenerative and chronic diseases like Alzheimer’s, Dementia with Lewy Bodies, Multiple System Atrophy, Parkinson’s, Migraine, and Hypercholesterolemia. On this episode of the Business of Biotech, the Chief Business Officer shares his inspiration and strategy for seeing therapeutics for big, global patient populations through the commercial finish line. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 26 Jun 2023 | Origins Of A Biopharma VC Deal With Bernat Olle, Ph.D. and Parag Shah | 01:14:40 | |
We love to hear from our listeners. Send us a message. Last October, we dropped an episode dissecting the relationship between Ray Therapeutics and one of its lead funders, 4BIO, and it quickly rocketed to an all-time Business of Biotech fan favorite. This week, we’re doing it again with a candid, behind-the-scenes breakdown of how Vedanta Biosciences secured the support of K2 Health Ventures in its recent $100 million+ financing to fund a pivotal Phase 3 study. Join us as we dissect a story that started when Vedanta CEO Bernat Olle, Ph.D. met K2HV’s Founding Managing Director & CEO Parag Shah on a mountain during the Timmerman Traverse. Their story serves as a guide to ensuring the cultural and strategic alignment of science and finance. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 03 Jul 2023 | Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD | 00:47:22 | |
We love to hear from our listeners. Send us a message. Ahmed Hamdy, MD didn’t ask to be the subject of Nathan Vardi's new book For Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 10 Jul 2023 | ML-Enabled Drug Discovery With LabGenius' James Field, Ph.D. | 00:46:58 | |
We love to hear from our listeners. Send us a message. Will machine learning revolutionize biopharma drug discovery? Has it already? This week on the Business of Biotech, we explore the intersection of tech and bio with Dr. James Field, founder and CEO of LabGenius. We'll get an insider's look at the formation of a company bridging the divide between computational and biological sciences, we'll learn why this ML-intensive leader applies a scientist's skepticism to the tech he's building, and we'll address fundamental data considerations along the way. We'll also learn about the challenges and opportunities that come with balancing a company that's building both a high-tech drug discovery platform and drugs themselves. If you're concerned with what ML will do to — or for — your biopharma business, don't miss this episode. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 17 Jul 2023 | COO Liftoff With Rocket Pharmaceuticals' Kinnari Patel, PharmD | 00:46:17 | |
We love to hear from our listeners. Send us a message. Chief Operating Officer is arguably the toughest job in the emerging biopharma C-suite. HR, CMC, regulatory affairs, legal, PR, you name it, the COO touches it, and practically everything rolls up to her. This week's episode of the Business of Biotech brings us to a president and COO who's also a mom, a volunteer, and an advocate for diversity and equality in biopharma. That advocacy isn't just lip service, by the way. Here, Rocket Pharmaceuticals' Kinnari Patel, PharmD, shares on the real, practical, replicable steps Rocket takes to build a diverse and equitable work environment, how the fruits of that effort have proven important to the company's success, and where Rocket is taking its high-flying gene therapy act next. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 24 Jul 2023 | Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard | 00:48:47 | |
We love to hear from our listeners. Send us a message. The microbiome therapeutics market has been taking a beating, with several clinical-stage companies failing or flailing at the hands of tough financial markets and regulatory scrutiny. MaaT Pharma Founder & CEO Hervé Affagard knows these perils well. Affagard recently navigated his company through a protracted FDA clinical hold, emerging on the other side with a promising Phase 3 candidate in Graft versus Host Disease. On this episode of the Business of Biotech, Affagard offers a transparent look at how MaaT is beating the odds with a redundant clinical strategy and scrupulous cash management. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 31 Jul 2023 | Establishing Research With Horizon Therapeutics' Robert Stoffel, Ph.D. | 00:47:22 | |
We love to hear from our listeners. Send us a message. While Horizon Therapeutics has made plenty of waves in the biotech news cycle of late. While perhaps not as flashy as a perilous multibillion dollar acquisition deal or potential blockbuster readout, its formal establishment of a research team – comparatively pragmatic as that may be – could have long-term consequences that are just impactful. On this week's episode of the Business of Biotech, we dig into why the company chose to establish a research function, learn why it chose Dr. Robert Stoffel, Ph.D. to run it, and get a step-by-step explainer on how Stoffel went about establishing the department, setting its goals and strategy, staffing it, and integrating it across teams at the fast-rising biopharmaceutical company. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 07 Aug 2023 | Biotech Cash Management with Allan Shaw | 00:47:38 | |
We love to hear from our listeners. Send us a message. It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. And, even when good data opens the cash floodgates, post-round cash management savvy isn't necessarily intuitive to academic and scientific founders. Cash runway preservation is, however, ingrained in the cerebral cortex of one of our favorite mavens of biotech finance markets and management, Mr. Allan Shaw. He joins us on this week’s episode of the Business of Biotech for a conversation on post-financing fundamentals for new and emerging biopharmas. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 14 Aug 2023 | Facing NASH Therapeutic Skepticism with 89bio's Rohan Palekar | 00:52:39 | |
We love to hear from our listeners. Send us a message. The non-alcoholic steatohepatitis (NASH) therapeutics market has proven to be an 11/10 on the difficulty scale. Despite billions of big biopharma dollars invested in therapeutic development, and a few close calls, no therapeutics has yet reached the finish line. On this episode of the Business of Biotech, 89bio CEO Rohan Palekar gives us the insider's perspective on the the challenges that heave beset the field, from a rigorous FDA approval process to poorly designed clinical trials and a wary investor base. Palekar also expresses optimism in his explanation of how, through a focus on safety, convenience, and cutting-edge testing technology to aid patient recruitment, 89bio is positioning itself to break the tape. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 21 Aug 2023 | Managing Momentum With Rezolute Bio's Nevan Charles Elam, JD | 00:53:35 | |
We love to hear from our listeners. Send us a message. Since we last spoke in the Spring of 2021, Nevan Charles Elam, JD has managed to advance both of small-but-mighty Rezolute Bio's candidates onto the next phases of their journey. This year, on the back of a $130 million investment, Rezolute Bio is prepping its RZ358 candidate, a monoclonal antibody for congenital hyperinsulinism, for a pivotal phase 3 trial. On this week's epsiode of the Business of Biotech, we're settling in for an interrogation of Elam on the management principles of maintaining multi-candidate clinical momentum among highly disparate candidates and raising big dollars as a small biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 28 Aug 2023 | Building LEO Pharma's U.S. Presence with Brian Hilberdink | 00:52:48 | |
We love to hear from our listeners. Send us a message. In many respects, bringing an established foreign biopharma company to the U.S. market is not unlike starting one up from scratch. In other respects, it's even harder; long-held cultural norms and management styles, region-specific market dynamics, payer system nuance, and political influence must all be re-navigated and re-negotiated without encumbrance. The job's not for the faint of heart, which might be why the Danish company LEO Pharma tapped veteran biopharma leader Brian Hilberdink to lead its U.S. operations. On this episode of the Business of Biotech, Hilberdink shares loads of biopharma-specific leadership intel and advice as we discuss the task he faces and the course he's charting. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 04 Sep 2023 | Fiscal Turnarounds with Protalix's Eyal Rubin | 00:51:53 | |
We love to hear from our listeners. Send us a message. Within about five minutes of conversation with Protalix CFO Eyal Rubin, I learned that he doesn’t bite his tongue about the rigors of biotech business and finance management, which is precisely why I’m eager to talk with him on today’s episode of the podcast. From commercialization deals with big pharma to being about $50 million underwater to swatting away the day trading armchair quarterbacks on Stocktwits, Rubin’s seen a few things and he’s developed more than a few opinions. On this episode of the Business of Biotech, you'll get a front-row seat to a discussion with a biotech CFO who knows how to put on the blinders, shut out distractions, right the ship and set the course to favorable financial waters. Bringing his years of experience in the CFO role at Teva Pharmaceuticals, Brainstorm Cell Therapeutics, and now, Protalix Biotherapeutics, we bring you Eyal Rubin for a story on big biopharma fiscal recoveries. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 11 Sep 2023 | Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin | 01:05:12 | |
We love to hear from our listeners. Send us a message. Core to the clinical-stage biopharma Life Bisociences belief set is that, "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.” The fountain of youth might be a fantasy, but the biology of aging, and more specifically, the science behind the manipulation of that biology, is not only real, it’s become big business. Still, the challenge for serious and legitimate biopharmaceutical companies in the anti-aging space can sometimes have less to do with biology than it does perception. Does the biotech investment community understand and embrace the concept? Equally, if not more importantly, will the FDA and other regulatory agencies lean into the idea that aging itself might be viewed as an indication that warrants therapeutic review? And from a commercial perspective, how does a legitimate biopharmaceutical company, focused on combatting the physical deterioration marked by the advance in our years, separate and differentiate itself from the billions of dollars being poured into the consumer packaged anti-aging and cosmetic medical procedures markets? On this episode of the Business of Biotech, Matt sits down with Life Biosciences' CEO Jerry McLaughlin to address these questions and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 18 Sep 2023 | Commercial Readiness with Orca Bio's Dan Kirby | 00:52:01 | |
We love to hear from our listeners. Send us a message. Orca Bio's Dan Kirby has played a hand in prepping more than a few approved biologic therapeutic candidates for commercialization. Equally important, he knows firsthand what makes or breaks post-approval commercial efforts, having played virtually every role there is to play in drug sales and marketing. He "carried the bag" for GSK in his early days, directed oncology marketing efforts at Amgen, and led marketing and U.S. commercial efforts at Juno, then Celgene after it acquired the former. Kirby joined Orca Bio in timely fashion back in 2020, as today the company ushers its first cell therapy into phase 3 clinical trials, with strategically-dispersed follow-up candidates spanning all phases back to R&D. On this week's episode of the Business of Biotech, we get a one-on-one commercialization preparation discussion with one of the best in the business, and the straight-talking veteran doesn't disappoint in the strategy and insight departments. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 25 Sep 2023 | Pragmatic Computational Biology with Andrew Satz | 00:59:16 | |
We love to hear from our listeners. Send us a message. This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware? In our talks with the leaders of new and emerging biotechs over the past 12 to 18 months, we've seen a steep increase in the application of – or at the very least, interest in – machine learning, AI, and computational biology tools for drug discovery, development, and beyond. Even those who are using some "ultra-light" application of new computational technology are eager to talk about it, as it’s clearly become as en-vogue as tacking “bio” onto your moniker was a few years back – even among companies who aren’t actually developing biologics. On this episode, Satz offers his take on the reality of adoption and shares advice on the fundamentals of AI and ML in biotech. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 02 Oct 2023 | Don't Be A D**k with Ochre Bio's Quin Wills, M.D., Ph.D. | 00:54:07 | |
We love to hear from our listeners. Send us a message. Don't be offended by the title of today's Business of Biotech podcast. Dr. Quin Wills' application of what's become known as "Wheaton's Law" (look it up) is central to the ambitious goals his company, Ochre Bio, is pursuing: pioneering the value of computational biology in large mol discovery and development, putting an end to the global liver disease epidemic, and changing the costly, high-risk approach to clinical trials. On this week's episode, Dr. Wills and I explore how those goals are being addressed despite the challenges they present, and how the company's three guiding principles, don't be a d*** being one of them, align the Ochre team with the mission at hand. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 09 Oct 2023 | Veteran Advice From The C-Suite with Citius' Leonard Mazur | 01:01:57 | |
We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, Leonard Mazur, co-founder, CEO, and chairman of Citius Pharmaceuticals, shares his rollercoaster ride to success in biotech, the founding story of Citius Pharmaceuticals, his engagement with the Department of Defense, and the effort to revive an antibiotic used on the frontlines. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 16 Oct 2023 | Bio Career Moves with Codagenix's Johanna Kaufmann, Ph.D. | 01:02:28 | |
We love to hear from our listeners. Send us a message. Johanna Kaufmann, Ph.D.'s path to EVP, Oncology at Codagenix is part serendipity and part circumstance, but it's a much larger part hard work. On this week's episode of the Business of Biotech, Dr. Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the personal professional and personal development regimens she subscribes to. We also catch up on the important work Codagenix is doing in the live vaccines and viral therapeutics arena. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 23 Oct 2023 | Clinical Leadership with Cue Biopharma's Anish Suri, Ph.D. & Dan Passeri, J.D. | 01:00:43 | |
We love to hear from our listeners. Send us a message. On a road trip to Boston, the Business of Biotech caught up with podcast alum Dan Passeri, J.D., CEO at Cue Biopharma, and enjoyed a two-for-one with CSO & President Anish Suri, Ph.D. at Cue's headquarters just feet below the Auerbach Center. Among other things, we discussed the duo's complementary leadership approach as the company takes multiple candidates into the clinic, why Passeri leans into his biotech legal background almost every day he's at work, the successful navigation of outsourced manufacturing relationships, why Cue's discretely targeted IL-2 approach eliminates the absurdity of early IL-2 failures, and a whole lot more. Speaking of Dan's legal background, before you jump into today's Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 30 Oct 2023 | CDMO + Emerging Bio Partnership with Forge's John Maslowski and Ray's Jenny Holt | 01:03:34 | |
We love to hear from our listeners. Send us a message. What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its contract develpment and manufacturing outsourcer (CDMO)? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align? Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 01 Nov 2023 | UPCOMING SPECIAL: Unraveling Biotech's Legal Enigmas With Keir LoIacono | 00:02:13 | |
We love to hear from our listeners. Send us a message. Register for Business of Biotech Live! Legal & IP Protection For New Biotechs here. Get ready to unravel the legal enigmas of the biotech world with me and Keir LoIacono, Esq. The CEO of Blue Sphere Bio, Keir is no stranger to high-stakes decision-making and legal conundrums in the biotech industry. Having served as the general counsel and VP of Corporate Development for Oncosec, lead in-house counsel and senior director for Advaxis, and intellectual property attorney at the leading biotech law firm Lerner, David, Littenberg, Krumholz, and Mentlick, Keir is a powerhouse of knowledge ready to share his insights. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 06 Nov 2023 | The Legendary Steve Gorlin's Golden Rules | 00:57:48 | |
We love to hear from our listeners. Send us a message. Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 13 Nov 2023 | RNA Delivery Business with Liberate's Shawn Davis, Ph.D. & Walter Strapps, Ph.D. | 00:54:40 | |
We love to hear from our listeners. Send us a message. Earlier this year, Shawn Davis, Ph.D. left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken, and others, before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Why'd they do it? Because RNA delivery is such a crucial step toward revolutionary genetic medicine, but it's tough science. They think they can change that. On this episode of the Business of Biotech, Drs. Davis and Strapps share how they're applying automation and machine learning technologies to minimize the challenges associated with targeted delivery of genetic medicine and overcome the limitations of AAV. During our conversation, they both leaned hard into how their previous experiences have shaped the work they're doing, and the wide-open business opportunities Liberate Bio is creating. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 20 Nov 2023 | Backpacks And Biotech with Luke Timmerman | 00:54:08 | |
We love to hear from our listeners. Send us a message. From his vantage point as an independent biotech journalist, Luke Timmerman has been watching the expansions and retractions of the industry for a couple of decades now. His unique perspective is hard to equal, and that perspective is, despite tough markets and tepid public sentiment, decidedly bullish. Luke's optimism is fed by sound logic gained from a career spent in observation mode, watching the development of purpose-built tools matched to address the fragility of human biology. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 27 Nov 2023 | Biotech Dealmaking with Regeneron's Nouhad Husseini | 01:02:44 | |
We love to hear from our listeners. Send us a message. When it comes to landing and executing strategic partnerships, Regeneron puts on a clinic. Partnerships, acquisitions, licensing agreements, and other deals large and small with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of those making news this year alone. The man behind much of that dealmaking is none other than Nouhad Husseini, SVP and Head of Business Development and Corporate Strategy at Regeneron. He’s a guy who’s deftly married the art and science of biopharma dealmaking, and on this episode of the Business of Biotech podcast, we’re getting introspective with this legend in the making, who our friend Allan Shaw says “turns the deals he touches into gold.” Strategic dealmaking is central to the biotech business, and today’s episode offers a master class. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 04 Dec 2023 | mRNA Vaccine Platforms with Combined Therapeutics' Dr. Romain Micol | 00:28:13 | |
We love to hear from our listeners. Send us a message. Combined Therapeutics President & CEO Dr. Romain Micol is operating his company in a very noisy space, where hundreds of new biotechs have popped up on the coattails of a COVID-driven renewal of interest in mRNA vaccines. Micol recognizes that noise and the competition it brings for capital and mindshare. He's not only aware of it — he welcomes it. On this quick episode of the Business of Biotech podcast, Micol shares the unique approach Combined Tx is taking to distinguishing itself in the mRNA infectious disease and cancer vaccine space, from the delivery, safety, efficay, and business perspectives. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 11 Dec 2023 | Public Sector Forged, Private Sector Tested with Renovaro BioSciences' Mark Dybul, M.D. | 01:03:40 | |
We love to hear from our listeners. Send us a message. During his leadership of the President's Emergency Plan for AIDS Relief during the George W. Bush administraion, Dr. Mark Dybul, M.D. shepherded programs credited with saving more than 25 million lives. For many years after that public service drew to a close, he continued the mission as executive director of The Global Fund to Fight AIDS, Tuberculosis and Malaria--working in lockstep with not only the world's leading scientists, but the likes of Bono and Sir Elton John along the way. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 18 Dec 2023 | IL-2 Program Profits with Bonum's Drs. John Mulligan and Neela Patel | 01:08:42 | |
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche. The asset, a PD-1-regulated IL-2 program, was a product of a platform that the new Bonum retains, and its sale to Roche was orchestrated by Dr. Patel. You've seen the terms of the deal in the news, but on this episode, you'll get the inside scoop on how the deal was done, how it set Bonum up for future paltform-driven succes, and how these two leaders retained its IP and its people through a fast, unique, and disruptive acquisition. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 25 Dec 2023 | Biotech Down Under with BiomeBank's Dr. Sam Costello | 01:06:13 | |
We love to hear from our listeners. Send us a message. Merry Christmas, Business of Biotechers! On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, a former gastroenterologist-turned managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind, anywhere in the world. In a segment of biotech that’s been particularly battered of late, that’s a big, big win. We also talked about what’s behind Australia’s foray onto the global biotech scene, the public/private partnerships supporting that growth, why U.S. biotechs, in particular, are flocking there to conduct clinical trials, and whether Foster’s is really Australian for beer. Don’t miss it! Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||
| 01 Jan 2024 | CDMO Collab with Scorpius BioManufacturing's Steve Lavezoli + Fina Biosolutions' Dr. Andrew Lees | 00:51:41 | |
We love to hear from our listeners. Send us a message. A new year marks a fresh start for biotech partnerships, and to kick off 2024, we're highlighting a good one. Fina Biosolutions' Dr. Andrew Lees recently signed on with Scorpius BioManufacturing to support his company's growth plan. On today's episode of the Business of Biotech, Lees sits down with Scorpius VP of commercial operations Steve Lavezoli for a frank conversation on the ups, downs, and expectations of a biotech + CDMO relationship. In addition to contracts and master service agreements, the pair walk us through the day-to-day execution of the partnership and responsibilities of those involved in it. If you're considering signing on with an outsourced manufacturing partner, or thinking about making a switch, you won't want to miss this episode. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. | |||